临床高危与首发精神病中GABAA受体可用性:[11C]Ro15-4513 PET研究
该研究用[11C]Ro15-4513 PET比较22例临床高危精神病个体、10例首发精神病患者与23名健康对照的GABAARα5可用性。海马GABAARα5可用性组间无显著差异,但脑网络协方差分析显示组间存在显著偏差,提示GABAARα5系统改变可能体现在全脑组织层面而非区域水平。
要点
- 海马GABAARα5可用性在临床高危、首发精神病与健康对照间无显著差异。
- GABAARα5协方差在全脑区域间及相对海马均显示组间显著偏差。
- 精神病人群GABAARα5异常可能表现为全脑网络组织改变而非区域水平变化。
核心结论
- 临床高危和早期精神病个体可能表现为GABAARα5系统全脑组织改变,而非区域水平变化。
研究设计与样本
- 用[11C]Ro15-4513 PET比较22例临床高危精神病个体、10例首发精神病患者和23名健康对照。
- 量化海马及全脑GABAARα5可用性,并用扰动协方差方法评估个体分子协方差偏差。
主要发现
- 海马GABAARα5可用性组间无显著差异(F(2,50)=0.25,p=0.78)。
- 全脑区域间GABAARα5协方差组间显著偏差(所有p<0.001,两两Cohen's d=0.07-0.5)。
- 相对海马的GABAARα5协方差组间显著偏差(所有p<0.001,两两Cohen's d=0.01-0.67)。
临床怎么用
- 解读精神病人群GABAARα5 PET结果时应关注全脑协方差网络而非仅海马区域可用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Disrupted gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of schizophrenia. Reductions in hippocampal GABAergic neurons have been found in schizophrenia, and increased hippocampal perfusion has been described in schizophrenia and in people at clinical high-risk for psychosis (CHRp). We have also found decreases in hippocampal GABAA receptors containing the α5 subunit (GABAARα5) in a well-validated neurodevelopmental rat model of relevance for schizophrenia. Positive allosteric modulation of these receptors in the hippocampus using a specific compound was shown to reverse the behavioural and neurophysiological phenotypes of this model. However, whether GABAARα5 availability is dysregulated in the psychosis spectrum at the regional or network levels is unknown. We addressed this issue by using [11C]Ro15-4513 and positron emission tomography (PET) in 22 individuals at CHRp, 10 people with a first-episode psychosis (FEP) and 23 healthy controls (HC). We quantified GABAARα5 availability in the hippocampus and across the brain, and employed a perturbation covariance method to assess individual molecular covariance deviations in CHRp and FEP groups compared to the HC group. Hippocampal GABAARα5 availability was not significantly different between groups (F(2,50) = 0.25, p = 0.78). However, network analysis identified significant deviations in GABAARα5 covariance between groups, both across all regions (all p < 0.001, pairwise Cohen's d = 0.07-0.5) and relative to the hippocampus (all p < 0.001, pairwise Cohen's d = 0.01-0.67). These findings suggest that individuals at clinical high-risk for psychosis and people with early psychosis may show alterations to the brain-wide organisation of the GABAARα5 system, rather than changes at a regional level.
引用
- Lukow PB, Schubert JJ, Severino M, et al. GABAA receptor availability in clinical high-risk and first-episode psychosis: a [11C]Ro15-4513 positron emission tomography study. Mol Psychiatry. 2025. PMID: 40914753. doi:10.1038/s41380-025-03204-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。